Sino Biopharmaceutical Limited (SBMFF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Wan Chai, 香港. 現CEOは S. Y. Tse.
SBMFF を有する IPO日 2010-02-22, 24,379 名の正社員, に上場 Other OTC, 時価総額 $13.58B.
Sino Biopharmaceutical Limited is a Hong Kong-incorporated research and development pharmaceutical conglomerate operating in China since 2000. The company develops and commercializes a diverse portfolio of pharmaceuticals across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as innovative chemical pharmaceuticals and parenteral nutritional products. Beyond pharmaceutical manufacturing, Sino Biopharmaceutical operates an integrated healthcare ecosystem comprising hospital operations, optometry services, health food production, pharmaceutical distribution, and medical technology consulting. The company organizes its operations through three main segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others, generating revenue from drug sales, healthcare services, and strategic investments.
